Tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage #SCLC (DeLLphi-303): a multicentre, phase 1b study
Presented today @IASLC#WCLC2025, 5 pm CEST
https://t.co/pGzVM7xha3
@ProvSwedCancRes
@DrKellyPaulson of @ProvSwedish presents international DeLLPhi-303 Ph1b trial at World Congress Lung Cancer in Barcelona on behalf of all centers: Overall Survival 25 months from start of ES-SCLC maintenance, compared to 10-15 mo in prior studies https://t.co/2qx9hQJtdA #WCLC25
Dr. Dubard-Gault cancer geneticist and preventionist @ProvSwedCancRes@ProvSwedish presents a rare cancer syndrome due to a newly described variant in JCO Precision Oncology: https://t.co/ww9wC4de9F
Struggling to juggle your daily tasks while keeping your energy levels up? It's time to focus on energy conservation for a better quality of life! Sonja Braasch, OTR/L, senior occupational therapist, shares how you can save #energy for the things you love and need to do. 💪💡
Please join us in welcoming our incoming class of physician #residents. Our residency program is known for its innovative learning environments, delivering on the Providence Mission and training our future physicians.
#ProvidenceSwedish#ProvidenceSwedishEverett#WSU
Sid Devarakonda, MD, expands on the significance of OS data when evaluating a treatment for efficacy in NSCLC and noted the potential value of additional end points including pCR and EFS. @ProvSwedCancRes#lcsm#oncology#MedTwitter https://t.co/Q03zqRsBYW
Sunshine Gray presents on nursing experience with #tarlatamab at the oncology nursing society congress. So glad for the critical efforts of our RNs on our research team and the recent FDA approval of this #bispecific for #smallcelllungcancer https://t.co/6u9lADP3Ma
Using AI deep learning to help understand cancer risk over time: no impact on vitamin D supplements on breast cancer risk using radiographic measures #swog https://t.co/KZNko4nfBI